On the upcoming delisting of ordinary shares of Syros Pharmaceuticals, Inc. (SYRS)
The International Trading System Limited (ITS) informs of the upcoming delisting of ordinary shares of Syros Pharmaceuticals, Inc. (ISIN US87184Q2066) from The NASDAQ Stock Market LLC (Nasdaq).
Information on forthcoming delisting of ordinary shares by Nasdaq
As previously disclosed, on March 10, 2025, Syros Pharmaceuticals, Inc. (the Company) filed a Form 25 with The United States Securities and Exchange Commission to remove the Company's common stock from listing and registration on Nasdaq effective on or about March 20, 2025.
Information regarding possible actions to be taken by ITS
ITS will publish separate notices on the procedures undertaken by ITS outlining how trading in these qualified investments will be carried out.
If Nasdaq suspends trading in the Company’s ordinary shares before the delisting, ITS will prohibit submission of orders and will restrict ability to conclude agreements in respect of the Company’s ordinary shares. When the Company’s ordinary shares are delisted from Nasdaq, ITS will terminate trading in the Company’s ordinary shares. However, in case the Company’s ordinary shares become listed, or admitted to trading on another Recognised Trading Venue, ITS will consider but does not guarantee continuation of trading in the Company’s ordinary shares.
03.03.2025 | On establishing a ban on submitting Orders and restricting ability to conclude Agreements in relation of ordinary shares of Syros Pharmaceuticals, Inc. (SYRS) |
03.03.2025 | On setting a condition under which Sell Orders may not be submitted in respect of ordinary share of Syros Pharmaceuticals, Inc. (SYRS) effective on 04.03.2025 |
03.03.2025 | On the expected delisting of ordinary shares of Syros Pharmaceuticals, Inc. (SYRS) |
13.01.2025 | Syros Pharmaceuticals, Inc. faces a higher risk of delisting from Nasdaq (SYRS) |
31.10.2024 | On the risk of delisting of ordinary shares of Syros Pharmaceuticals, Inc. (SYRS) |